Professional Licensing Agency 402 West Washington Street Room W072 Indianapolis, Indiana 46204



Michael R. Pence Governor of Indiana Nicholas W. Rhoad PLA Executive Director

Optometrists,

Pursuant to <u>House Enrolled Act 1184</u>, optometrists have the ability to prescribe Tramadol, a Schedule IV controlled substance. There are several prerequisites an optometrist must complete before being able to write prescriptions for Tramadol.

The Optometric Legend Drug Certificate issued by the Indiana Optometry Board does not provide authority to write prescriptions for Tramadol. Each practitioner who wishes to prescribe Tramadol will be required to also obtain a Controlled Substances Registration (CSR). The CSR does not replace the Legend Drug Certificate. Practitioners holding a CSR must also hold the Optometric Legend Drug Certificate. Questions regarding CSRs or the application process should be directed to the Indiana Optometry Board at pla14@pla.in.gov or (317) 234-8800.

Once the CSR has been issued, the practitioner must then apply for a Federal Drug Enforcement Administration (DEA) Registration number. Information about applying for a DEA number and a link to the application are found on the <u>DEA's website</u>. Detailed instructions are also available <u>here</u>.

There are specific requirements for writing a prescription for a controlled substance, which can be found on the PLA's website by clicking here.

State law requires that all controlled substance prescriptions must be written on security prescription pads obtained from an approved vendor. Optometrists writing prescriptions for Tramadol will be required to purchase security prescription pads through an approved vendor. A list of approved vendors can be viewed here. Questions about security prescriptions should be addressed to the Indiana Board of Pharmacy at pla4@pla.in.gov or (317) 234-2067.

Also available, the link to the security features prescription paper template: http://www.in.gov/pla/files/Security Feature Prescription Paper Template(7).pdf.

Lastly, all prescriptions written for Tramadol must be reported to the INSPECT Program within 7 days. As of July 1, 2015, it will be required of prescribers and dispensers to report to INSPECT within 3 days. The INSPECT program is a tool to address the problem of prescription drug abuse and diversion in Indiana. If you hold a CSR, you may access patient information through INSPECT. An INSPECT report summarizes the controlled substances a patient has been prescribed, the practitioner who prescribed them and the dispensing pharmacy where the patient obtained them. Registration with INSPECT is required in order to access patient information; click here for more information.

Questions about INSPECT should be directed to inspect@pla.in.gov or (317) 234-2115.